Loading patent…
AssigneeSignal Pharmaceuticals, LLC
InventorsYuhong L. Ning, Weiming Xu, Rajesh Chopra, Peter Worland, Shuichan Xu
Estimating the term…
Provided herein are methods for predicting the LKB1 status of a patient or a biological sample, comprising the measurement of particular gene expression levels relative to a set of reference levels that represent the gene expression level of a biological wild-type sample without LKB1 gene or protein loss or mutation and the gene expression level of a reference sample with LKB1 gene or protein loss or mutation. Further provided herein are methods for treating and/or preventing a cancer or a tumor syndrome in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having cancer or a tumor syndrome, characterized by particular gene expression levels.
A method for predicting LKB1 gene or protein loss or mutation in a patient's cancer, comprising:
A method for treating non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome, comprising administering an effective amount of a TOR kinase inhibitor to a patient having non-small cell lung carcinoma, cervical cancer or Peutz-Jeghers Syndrome, wherein the gene expression level of a biological test sample from said patient is characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation than the gene expression level of a wild type sample without LKB1 gene or protein loss or mutation, and wherein the genes are selected from Table 1.
A method for treating non-small cell lung carcinoma or cervical cancer, comprising screening a patient's carcinoma or cancer for the presence of LKB1 gene or protein loss or mutation, relative to wild type, and administering an effective amount of a TOR kinase inhibitor to the patient having non-small cell lung carcinoma or cervical cancer characterized by a gene expression level characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation than the gene expression level of a wild type sample without LKB1 gene or protein loss or mutation, and wherein the genes are selected from Table 1.
A method for treating Peutz-Jeghers Syndrome, comprising comparing a patient's gene expression level to wild type, and administering an effective amount of a TOR kinase inhibitor to the patient having Peutz-Jeghers Syndrome characterized by a gene expression level characterized by higher similarity to the gene expression level of a reference sample with LKB1 gene or protein loss or mutation than the gene expression level of a wild type sample without LKB1 gene or protein loss or mutation, and wherein the genes are selected from Table 1.
A method of predicting response to treatment with a TOR kinase inhibitor in a patient having cancer, the method comprising:
A kit comprising one or more containers filled with a TOR kinase inhibitor or a pharmaceutical composition thereof, reagents for measuring gene expression levels of a patient's cancer or of a patient having a tumor syndrome and instructions for measuring gene expression levels of a patient's cancer or of a patient having a tumor syndrome.
Dependencies are inferred from the claim text.